16 January 2012
The data are presently evaluated but already it may be concluded that the results are positive and that the primary efficacy parameters are met.
In 2007 NattoPharma initiated a 3-year clinical intervention study on the effects of MenaQ7® on bone and cardiovascular health, respectively. Recruitment for the study started in early 2008 and the last measurements have been completed in the fall of 2011. The compliance was excellent - with 91.4% of the randomized participants staying in the study until its completion. The data are presently evaluated but already it may be concluded that the results are positive and that the primary efficacy parameters are met.
"The results from the 3 year human study on MenaQ7® are encouraging. This is the first time in history such effects have been scientifically documented with natural vitamin 2K" says CEO Peter Carlsson and continues "- it is an essential step for NattoPharma to get this confirmation, and we will actively use the findings together with our customers and partners to improve our commercial platform. NattoPharma has made a significant investment in this study and is working on expanding its partnerships with leading companies commercializing MenaQ7® in the supplement and functional food markets throughout the world."
Background
In April 2008, NattoPharma started a clinical
intervention study with 244 postmenopausal women
randomized to receive either MenaQ7® or placebo. The
study has been conducted at VitaK at the Maastricht
University in the Nederland's and lead by Associate
Professor of Biochemistry Cees Vermeer. The aim of the
study was to investigate the effects of a sustained
intake of a low dose (180 mcg) of natural vitamin K2
(MenaQ7®) on both bone and vascular health parameters.
Final results of this clinical study are expected to be
released during 2012 and are likely to generate several
scientific publications. The results will also be used
for the important regulatory work worldwide.
Cardiovascular Health
Cardiovascular disease (CVD) is the most common cause of
death in the Western society. In Europe cardiovascular
mortality amounts 4.5 million each year. With increasing
problems of obesity and type-2 diabetes, which are strong
risk factors, CVD is expected to increase not only in the
Western world but especially in Asia. Any component that
can prevent the development of CVD is therefore of
significant importance. The study shows that MenaQ7® has
positive effects on several CVD-parameters; among several
findings the pulse wave velocity parameter improved
significantly by MenaQ® treatmen
Osteoporosis
Osteoporosis is a disease that leads to an increased risk
of fractures of bones. In osteoporosis the bone mineral
density (BMD) is reduced, bone micro architecture
deteriorates, and the amount and variety of proteins in
the bone is altered. According to the International
Osteoporosis Foundation, osteoporosis it is estimated to
affect 75 million people in Europe, USA and Japan. The
results of NattoPharma's current study show that
MenaQ7® plays a positive role in bone health. Both the
amount of bone and quality of bone are better conserved
in the MenaQ7® group.
About MenaQ7®
MenaQ7 provides natural vitamin K2 as a fermentation
extract whereby vitamin K2 is manufactured using
bascillus subtilis natto. This process has the capacity
of producing the highly pure and bio-available form of
vitamin K2, menaquinone-7 (MK-7). MenaQ7® is the best
documented, commercially available natural vitamin K2
with guaranteed actives and stability.Nattopharma holds
several granted and pending patents that protect the use
of K vitamins.
For more information on the health benefits of MenaQ7®, please visit www.menaq7.com
About NattoPharma
NattoPharma, Norway is the exclusive international
supplier of MenaQ7®, the natural vitamin K2. NattoPharma
has entered into a multi-year research and development
program to substantiate and discover the health benefits
of natural vitamin K2 for applications in the exciting
marketplace for functional food and health food
supplements.
Please visit www.nattopharma.com
For more information, please contact
Peter Carlsson
CEO
Phone: +47 950 49 906
Dan Edwall
R&D Manager
Phone: +46 70 798 80 89
distribué par | Ce noodl a été diffusé par Nattopharma ASA et initialement mise en ligne sur le site http://www.nattopharma.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-16 18:43:44 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |